Current treatment modalities provide limited improvement in the natural course of lung
cancer, and prognosis remains poor. Lung cancer is a malignancy with great molecular …

Novel therapies have been added to the treatment arsenal of physicians treating lung
cancer in recent years. Most promising are agents that target the major pathways involved in …

Conventional therapy for non-small cell lung cancer (NSCLC) has reached a plateau in
increasing patient survival and overall prognosis still remains dismal. Advances in the …

Lung cancer remains the leading cause of malignancyrelated mortality worldwide with over
a million cases diagnosed yearly. Non-small cell lung cancer (NSCLC) accounts for more …

New agents directed against molecular targets have now been tested in large prospectively
randomized clinical trials for patients with untreated advanced non-small cell lung cancer …

Lung cancer remains the leading cause of malignancy-related mortality worldwide, with over
one million cases diagnosed yearly. Non-small-cell lung cancer (NSCLC) accounts for> …

The major progresses in understanding cancer biology and the mechanism of oncogenesis
have allowed the development of several potential molecular target drugs for cancer …

Platinum-based doublet chemotherapy is the standard treatment for advanced non-small-
cell lung cancer, with a median survival and 1-year survival of 8-10 weeks and 30-40 …

Recent progress in molecular biology has enabled us to better understand the molecular
mechanism underlying pathogenesis of human malignancy including lung cancer, the …

The outcome of treatments for non-small-cell lung cancer (NSCLC) can still be considered to
be disappointing [1]. Advances in knowledge about tumour biology and mechanisms of …